Future prospects for targeted alpha therapy

Current Radiopharmaceuticals

Volumn 4, Issue 4, 2011, Pages 336-342

  Allen, Barry J ^a  

^a St George Dermatology and Skin Cancer Centre   (Australia)

Author keywords

Alpha sources; Biological dosimetry; Clinical trials; Microdosimetry; Monoclonal antibodies; Monte carlo calculations; Radioisotopes; Targeted alpha therapy; Toxicity; Tumor anti vascular alpha therapy; Tumor vasculature

Indexed keywords

ACETYLSALICYLIC ACID; ACTINIUM 225; AMPHETAMINE; ANTIBODY CONJUGATE; ASTATINE 211; BISMUTH 212; BISMUTH 213; CD20 ANTIBODY; LUTETIUM 177; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 18 B7; MONOCLONAL ANTIBODY 81C6; MONOCLONAL ANTIBODY 9 2 27; MONOCLONAL ANTIBODY C 595; MONOCLONAL ANTIBODY M 195; MONOCLONAL ANTIBODY MX 35; PETHIDINE; RADIOISOTOPE; RADIUM; RADIUM 223; SUBSTANCE P; TERBIUM; TERBIUM 149; UNCLASSIFIED DRUG; WARFARIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT THERAPY; ARTICLE; BIOAVAILABILITY; BONE CANCER; CANCER CELL; CANCER RADIOTHERAPY; CAPILLARY PERMEABILITY; CARCINOMATOSIS; CARDIOVASCULAR SYSTEM; CELL ISOLATION; DRUG DISTRIBUTION; GLIOBLASTOMA; GLIOMA; HALF LIFE TIME; HUMAN; IMAGING; IMMUNOTHERAPY; ISOTOPE LABELING; LYMPHOMA; MELANOMA; MICRODOSIMETRY; MONTE CARLO METHOD; MYCOSIS; NUCLEAR MEDICINE; OVARY CANCER; PERITONEAL CARCINOMATOSIS; PERIVASCULAR SPACE; PRIORITY JOURNAL; RADIATION DOSE; TARGET CELL; TARGETED ALPHA THERAPY; TOXICITY;

EID: 80052203481     PISSN: 18744710     EISSN: 18744729     Source Type: Journal    
DOI: 10.2174/1874471011104040336     Document Type: Article

References (22)

1. Köhler. G.; Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 1975, 256, 495-497.
2. D.M. Targeted therapy of cancer with radiolabeled antibodies. J. Nucl. Med., 2002, 43, 693-713.
3. Brons, S.; Jakob, B.; Taucher-Scholz, G.; Kraft, G. Heavy ion production of single- and double-strand breaks in plasmid DNA in aqueous solution. Phys. Med., 2001, 17, 217s-218s.
4. J.F. A histochemical study of hypertrophy and ischaemic injury of rat liver with special reference to changes in lysosomes. J. Path. Bact., 1965, 90, 419-435.
5. Sgouros, G. Radioimmunotherapy of micrometastases: sidestepping the solid tumor hurdle. J. Nucl. Med., 1995, 36, 1910-1912.
6. Allen, B.J.; Raja, C.; Abbas Rizvi, S.M.; Song, E.Y.; Graham, P. Tumour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer. Phys. Med. Biol., 2007, 52, 15-19.
7. Jurcic, G.J.; Larson, S.M.; Sgouros, G.; McDevitt, M.R.; Finn, R.D.; Divgi, C.R.; Ballangrud, A.M.; Hamacher, K.A.; Ma, D.; Humm, J.L.; Brechbiel, M.W.; Molinet, R.; Scheinberg, D.A. Targeted alpha particle immunotherapy for myeloid leukaemia. Blood, 2002, 100, 1233-1239.
8. Raja, C.; Graham, P.; Abbas Rizvi, S.M.; Song, E.; Goldsmith, H.; Thompson, J.; Bosserhoff, A.; Morgenstern, A.; Apostolidis, C.; Kearsley, J.H.; Reisfeld, R.; Allen, B.J. Interim analysis of toxicity and response in Phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol. Ther., 2007, 6, 846-852.
9. th Alpha- Immunotherapy Symposium; Morgenstern, A., Ed.; Institute for Transuranium Elements: Dusseldorf, Germany, 2004; pp. 12.
10. 211Atlabeled chimeric anti-tenascin monoclonal antibody 81C6. J. Nucl. Med., 2008, 49(1), 30-38.
11. 213Bi-DOTA-[Thi8,Met(O2)11]- substance P: a pilot trial. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37, 1335-1344.
12. 211At-MX35 F(ab́)2 - a phase 1 study. J. Nucl. Med., 2009, 50(7), 1153-1160.
13. Allen BJ, Abbas Rizvi SM, Qu CF, Smith RC. Targeted alpha therapy approach to the management of pancreatic cancer. Cancers 2011, 3, 1821-1843
14. Dadechova E, Nakouzi A, Bryan R, Casadevill A. Ionising radiation delivered by a specific antibody is therapeutic against a fungal infection. Proc Nat Acad Sci USA, 2003, 100, 10942-10947
15. B.J. Clinical trials of targeted alpha therapy for cancer. Rev. Rec. Clin. Trials, 2008, 3, 185-191.
16. Allen, B.J.; Raja, C.; Abbas Rizvi, S.M.; Graham, P.; Kearsley, J.H. New directions for clinical trials of targeted alpha therapy for metastatic melanoma. Curr. Radiopharm., 2008, 1, 240-250.
17. Martin, V.M.; Sieqwert, C.; Scharl, A.; Harms, T.; Heinze, R.; Ohl, S.; Radbruch, A.; Miltenyi, S.; Schmitz, J. Immunomagnetic enrichment of disseminated epithelial tumour cells from peripheral blood by MACs. Exp. Haem., 1998, 26, 252-264.
18. 213Bilabeled multiple targeted alpha immuno-conjugates. Prostate, 2006, 66, 1753-1767.
19. Azzam, E.I.; Little, J.B. The radiation-induced bystander effect: evidence and significance. Hum. Exp. Toxicol., 2004, 23, 61-65.
20. Song, E.Y.; Abbas Rizvi, S.M.; Raja, C.; Qu, C.F.; Yuen, J.; Morgenstern, A.; Apostolidis, C.; Allen, B.J. The cytokinesis-block assay as a biological dosimeter for targeted alpha therapy. Phys. Med. Biol., 2008, 53, 319-328.
21. 213Bi-cDTPA-9.2.27 in lacZ transgenic mice. Cancer Biol. Ther., 2009, 8(9), 777-781.
22. 213Bi. Eur. J. Nucl. Med. Mol. Imaging, 2011, 38(2), 312-322.